卡培他滨联合奥沙利铂同步放化疗对根治术后晚期直肠癌患者的效果观察  

Effects of Concurrent Chemoradiotherapy with Capecitabine and Oxaliplatin on Advanced Rectal Cancer after Radical Resection

作　　者：梁江[1] 赵虹琇 郑茂东[1] 颜娟[1] 赵御森[2] LIANG Jiang;ZHAO Hong-xiu;ZHENG Mao-dong;YAN Juan;ZHAO Yu-sen(Department of Pharmacy,the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, China;Department of CT Room, the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, China)

机构地区：[1]河北北方学院附属第一医院药学部,河北张家口075000 [2]河北北方学院附属第一医院CT室,河北张家口075000

出　　处：《临床误诊误治》2019年第4期34-38,共5页Clinical Misdiagnosis & Mistherapy

基　　金：河北省2014年度医学科学研究重点课题(ZD20140167)

摘　　要：目的探讨卡培他滨联合奥沙利铂同步放化疗对根治术后晚期直肠癌患者的临床效果。方法选取河北北方学院附属第一医院2013年5月—2015年5月收治的晚期直肠癌患者93例,采用随机数字表法分为观察组46例和对照组47例。对照组患者在直肠癌根治术后采用卡培他滨联合奥沙利铂化疗,观察组患者在对照组治疗基础上联合同步放疗。治疗1年后比较两组近期临床疗效,随访3年比较两组患者3年生存率、复发率、远处转移率,以及治疗期间不良反应发生情况。结果①治疗1年后,观察组患者治疗总有效率为80.43%显著高于对照组的65.96%(χ~2=6.391,P=0.003);②观察组患者2、3年生存率明显高于对照组患者(χ~2=9.176,P=0.002;χ~2=8.256,P=0.013);③观察组患者3年复发率及远处转移率均显著低于对照组患者(χ~2=6.203,P=0.015;χ~2=7.338,P=0.004);④两组患者治疗期间不良反应发生率比较差异均无统计学意义(P>0.05)。结论晚期直肠癌患者在根治术后采用卡培他滨联合奥沙利铂同步放化疗,能够有效提高患者临床治疗效果,延长生存期,降低复发率及远处转移率,而且并未升高不良反应发生率。Objective To investigate the clinical effect of concurrent chemoradiotherapy with capecitabine and oxaliplatin in the treatment of advanced rectal cancer after radical resection. Methods Ninety-three patients with advanced rectal cancer who were admitted to the First Affiliated Hospital of Hebei Northern University from May 2013 to May 2015 were randomly divided into observation group ( n =46) and control group ( n =47). Patients in the control group received chemotherapy with capecitabine combined with oxaliplatin after radical resection of rectal cancer, while patients in the observation group received concurrent radiotherapy on the basis of the control group. One year after treatment, the short-term clinical efficacy was compared between the two groups. The 3-year survival rate, recurrence rate, distant metastasis rate and adverse reactions during treatment were compared between the two groups after 3-year follow-up. Results After one year of treatment, the total effective rate of the observation group was 80.43%, which was significantly higher than that of the control group (65.96%)(χ 2=6.391, P =0.003). The 2-year and 3-year survival rates of the observation group were significantly higher than those of the control group (χ 2= 9.176, P =0.002;χ 2=8.256, P =0.013). The 3-year recurrence rate and distant metastasis rate were significantly lower than those of the control group (χ 2=6.203, P =0.015;χ 2=7.338, P =0.004). There was no significant difference in the incidence of adverse reactions between the two groups ( P >0.05). Conclusion Capecitabine combined with oxaliplatin in the treatment of advanced rectal cancer after radical surgery can effectively improve the clinical efficacy, prolong the survival time of patients, reduce the recurrence rate and distant metastasis rate, and does not increase the incidence of adverse reactions of patients.

关 键 词：直肠肿瘤 结直肠外科手术 卡培他滨 奥沙利铂 放化疗 

分 类 号：R735.37[医药卫生—肿瘤]